Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
STAR Protoc ; 2(4): 100934, 2021 12 17.
Artículo en Inglés | MEDLINE | ID: mdl-34816127

RESUMEN

Identification of non-coding mutations driving tumorigenesis requires alternative approaches to coding mutations. Enriched associations between mutated regulatory elements and altered cis-regulation in tumors are a promising approach to stratify candidate non-coding driver mutations. Here we provide a bioinformatics pipeline to mine data from the Cancer Genomic Commons (GDC) for such associations. The pipeline integrates RNA and whole-genome sequencing with genotyping data to reveal putative non-coding driver mutations by cancer type. For complete information on the generation and use of this protocol, please refer to Cheng et al. (2021).


Asunto(s)
Carcinogénesis/genética , Biología Computacional/métodos , Mutación/genética , Neoplasias/genética , Secuencias Reguladoras de Ácidos Nucleicos/genética , Bases de Datos Genéticas , Humanos
2.
iScience ; 24(3): 102144, 2021 Mar 19.
Artículo en Inglés | MEDLINE | ID: mdl-33665563

RESUMEN

Despite the recent availability of complete genome sequences of tumors from thousands of patients, isolating disease-causing (driver) non-coding mutations from the plethora of somatic variants remains challenging, and only a handful of validated examples exist. By integrating whole-genome sequencing, genetic data, and allele-specific gene expression from TCGA, we identified 320 somatic non-coding mutations that affect gene expression in cis (FDR<0.25). These mutations cluster into 47 cis-regulatory elements that modulate expression of their subject genes through diverse molecular mechanisms. We further show that these mutations have hallmark features of non-coding drivers; namely, that they preferentially disrupt transcription factor binding motifs, are associated with a selective advantage, increased oncogene expression and decreased tumor suppressor expression.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA